Finance

Lists
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,20 ฿
0,00%
(0,00) 1D
15 հոկ, 16:40:00 GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for WUXI06...
Open
5,25 ฿
High
5,35 ฿
Low
5,05 ฿
Mkt. cap
198,43 մլրդ
Avg. vol.
93,60 հզր
Volume
288,50 հզր
52-wk high
6,25 ฿
52-wk low
3,02 ฿
Shares outstanding
4,12 մլրդ
No. of employees
15 հզր
Open
5,25 ฿
High
5,35 ฿
Low
5,05 ฿
Mkt. cap
198,43 մլրդ
Avg. vol.
93,60 հզր
Volume
288,50 հզր
52-wk high
6,25 ฿
52-wk low
3,02 ฿
Shares outstanding
4,12 մլրդ
No. of employees
15 հզր
News stories
From web sources and news partners
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics (Cayman) Inc. KKPS DR
CEOZhisheng Chen
Employees14,7 հզր
Founded2010
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
5,92 մլրդ
5,92 մլրդ
5,89 մլրդ
5,89 մլրդ
Cost of goods sold
3,04 մլրդ
3,04 մլրդ
3,17 մլրդ
3,17 մլրդ
Cost of revenue
3,04 մլրդ
3,04 մլրդ
3,17 մլրդ
3,17 մլրդ
Research and development expenses
254,93 մլն
254,93 մլն
215,11 մլն
215,11 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
631,03 մլն
631,03 մլն
591,61 մլն
591,61 մլն
Operating expense
921,71 մլն
921,71 մլն
860,09 մլն
860,09 մլն
Total operating expenses
3,96 մլրդ
3,96 մլրդ
4,03 մլրդ
4,03 մլրդ
Operating income
1,96 մլրդ
1,96 մլրդ
1,86 մլրդ
1,86 մլրդ
Other non operating income
33,58 մլն
33,58 մլն
42,20 մլն
42,20 մլն
EBT including unusual items
1,96 մլրդ
1,96 մլրդ
1,71 մլրդ
1,71 մլրդ
EBT excluding unusual items
1,94 մլրդ
1,94 մլրդ
1,70 մլրդ
1,70 մլրդ
Income tax expense
476,10 մլն
476,10 մլն
251,54 մլն
251,54 մլն
Effective tax rate
24,24%
24,24%
14,71%
14,71%
Other operating expenses
-
-
-
-
Net income
1,28 մլրդ
1,28 մլրդ
1,22 մլրդ
1,22 մլրդ
Net profit margin
21,70%
21,70%
20,70%
20,70%
Earnings per share
-
-
-
-
Interest and investment income
115,29 մլն
115,29 մլն
106,38 մլն
106,38 մլն
Interest expense
-29,76 մլն
-29,76 մլն
-22,28 մլն
-22,28 մլն
Net interest expenses
85,53 մլն
85,53 մլն
84,10 մլն
84,10 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
2,24 մլրդ
2,24 մլրդ
2,27 մլրդ
2,27 մլրդ
Gain or loss from assets sale
317,34 մլն
317,34 մլն
-
-
AI content may include mistakes. Learn more
Google Apps